Literature DB >> 8674058

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.

K C Xie1, W Plunkett.   

Abstract

The action of the new adenine nucleoside analogue 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (Cl-F-ara-A) on DNA synthesis was evaluated both in whole cells and in vitro assay systems with purified DNA polymerases. [3H]Thymidine incorporation into DNA in human lymphoblastoid CEM cells was inhibited by Cl-F-ara-A in a concentration-dependent manner that was not reversed 72 h after removal of Cl-F-ara-A from the medium. Deoxynucleotide pools were depressed after incubation of Cl-F-ara-A for 3 h and only partially recovered following washing the cells into drug-free medium. The most pronounced decrease occurred in the dCTP pool, quantitatively followed by the dATP, dGTP, and dTTP pools. This was in concordance with the results of in situ assays of ribonucleotide reductase, which demonstrated profound inhibition of CDP reduction in cells incubated with Cl-F-ara-A; reduction of ADP, GDP, and UDP were affected to lesser extents. Reductase activity was inversely correlated with the cellular Cl-F-ara-ATP level, and inhibition of the enzyme was saturated when cellular Cl-F-ara-ATP reached 25 microM. In vitro DNA primer extension assays indicated that Cl-F-ara-ATP competed with dATP for incorporation into A sites of the extending DNA strand catalyzed by both human DNA polymerases alpha and epsilon. The incorporation of Cl-F-ara-AMP into DNA inhibited DNA strand elongation; the most pronounced effect was observed at Cl-F-ara-ATP:dATP values >1. The sustained inhibition of ribonucleotide reductase and the consequent depletion of deoxynucleotide triphosphate pools result in a cellular concentration ratio of dATP to Cl-F-ara-ATP, which favors analogue incorporation into DNA, an action that has been strongly correlated with loss of viability.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674058

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

Authors:  Koen van Besien; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Lucy A Godley; Peter H O'Donnell; Justin Kline; Vu Nguyen; Paula Del Cerro; Richard A Larson; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-09       Impact factor: 5.742

2.  Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.

Authors:  Anna Fyrberg; Kourosh Lotfi
Journal:  Cytotechnology       Date:  2010-10-19       Impact factor: 2.058

3.  Clofarabine: in pediatric patients with acute lymphoblastic leukemia.

Authors:  Monique P Curran; Caroline M Perry
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Authors:  Amer M Zeidan; Rebecca M Ricklis; Hetty E Carraway; Hyun D Yun; Jacqueline M Greer; B Douglas Smith; Mark J Levis; Michael A McDevitt; Keith W Pratz; Margaret M Showel; Douglas E Gladstone; Steven D Gore; Judith E Karp
Journal:  Br J Haematol       Date:  2012-05-18       Impact factor: 6.998

5.  Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.

Authors:  Kristie A Blum; Mehdi Hamadani; Gary S Phillips; Gerard Lozanski; Amy J Johnson; David M Lucas; Lisa L Smith; Robert Baiocchi; Thomas S Lin; Pierluigi Porcu; Steven M Devine; John C Byrd
Journal:  Leuk Lymphoma       Date:  2009-03

6.  Clofarabine 5'-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit.

Authors:  Yimon Aye; Joanne Stubbe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

7.  Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms.

Authors:  Akshay Sharma; Guolian Kang; Anusha Sunkara; Hiroto Inaba; Sima Jeha; Shane J Cross; Terrence Geiger; Brandon Triplett
Journal:  J Pediatr Hematol Oncol       Date:  2018-11       Impact factor: 1.289

8.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

9.  Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers.

Authors:  Yimon Aye; Edward J Brignole; Marcus J C Long; Johnathan Chittuluru; Catherine L Drennan; Francisco J Asturias; JoAnne Stubbe
Journal:  Chem Biol       Date:  2012-07-27

10.  Use of clofarabine for acute childhood leukemia.

Authors:  A Pession; R Masetti; K Kleinschmidt; A Martoni
Journal:  Biologics       Date:  2010-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.